Listen on the go
CORRECT!
Next question
touchENDOCRINOLOGY touchENDOCRINOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Obesity

    An Introduction to Obesity

    The prevalence of obesity is increasing worldwide and along with it the economic burden of obesity-related complications. Several pharmacotherapies have been approved to, suppress appetite and reduce lipid absorption, although lifestyle and behavioural changes remain the mainstay of the treatment paradigm. Research into SGLT-2 inhibitors, amylin mimetics, leptin analogues and ghrelin antagonists as potential treatments are ongoing.

    Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.

    Obesity Content

    touchINSIGHT
    Shaping obesity care with evidence-based, personalised treatments
    For HCPs in: Europe
    View Time: 6 mins Sponsored content

    Watch a leading expert discuss the need for personalised obesity treatment including current evidence for cardiovascular outcomes.

     

    Date of Preparation: December 2024
    Diabetes, Obesity
    Building a legacy: Dr Sanjay Kalra’s endocrinology journey

    In this expert Q&A we are delighted to welcome our Editorial Board member Dr Sanjay Kalra, a leading endocrinologist with over two decades of experience at Bharti Hospital, Karnal, India. A passionate educator and researcher, Dr Kalra serves as Education Editor of the International Society of Endocrinology (ISE) and is deeply involved in global endocrine education. His leadership extends to roles such as Immediate Past President of the Endocrine Society of India and Vice-President of the South Asian Federation of Endocrine Societies.

    Obesity
    Dual GLP-1/GLP-2 receptor agonist, dapiglutide, shows similar weight loss to placebo but may aid weight reduction
    Watch Time: 6 mins

    Dapiglutide is a once-weekly, subcutaneous dual GLP-1/GLP-2 receptor agonist being investigated for the treatment of obesity. This first-in-class molecule is designed to take advantage of the weight-loss effects of GLP-1 agonist and the additional benefit of a  GLP-2 agonist on improving intestinal barrier function and addressing co-morbidities associated with low-grade inflammation seen in obesity.

    Obesity
    Liraglutide safe and effective to treat obesity in children under 12 years
    Claudia Fox Watch Time: 4 mins

    The SCALE Kids trial (NCT04775082) is the first randomized, placebo-controlled, phase 3 study examining the use of liraglutide 3.0 mg in children aged 6 to <12 years with obesity. The trial addresses a crucial gap in paediatric obesity treatment, aiming to establish the safety and efficacy of liraglutide in children under 12, where no approved medications exist, alongside lifestyle interventions such as diet and physical activity.

    Diabetes, Obesity
    Expert Q&A: Prof. Pappachan on career success and innovations in endocrinology

    We're excited to introduce a new series of expert Q&As featuring members of the touchREVIEWS in Endocrinology editorial board and faculty. In this series, they will share key career milestones, offer valuable advice for aspiring future leaders, and provide forward-looking insights into their areas of expertise.

    Obesity
    EASO release new framework for the diagnosis, staging and management of obesity in adults

    The European Association for the Study of Obesity (EASO) has introduced a new framework for the diagnosis, staging and management of obesity in adults.

    Obesity
    Glucose
    Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis
    Deep Dutta, A.B.M. Kamrul-Hasan, Lakshmi Nagendra

    touchREVIEWS in Endocrinology. 2024;20(2):72–80

    Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1 Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and five times lower GLP-1 receptor affinity than native GLP-1.1 Several systematic reviews and meta-analyses (SRMs) have been […]

    Diabetes, Obesity, Pituitary Disorders, Thyroid Disorders
    Foreword: touchREVIEWS in Endocrinology 20.1

    Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from Eleni Armeni and Ashley Grossman on seliciclib, a potential new treatment for patients with Cushing’s […]

    Obesity
    Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction
    Sulmaaz Qamar, Ritwika Mallik, Janine Makaronidis

    touchREVIEWS in Endocrinology. 2024;20(2):62–71

    Obesity defined as abnormal or excessive fat accumulation that presents a risk to health, is a chronic disease linked to metabolic co-morbidities, such as type 2 diabetes mellitus and cardiovascular disease, a reduced life expectancy, economic burden and reduced quality of life.1 Worldwide obesity rates nearly tripled from 1975 to 2016, with over 650 million adults […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchENDOCRINOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup